Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Guide13 min read

Compounded Semaglutide Units to mg: How to Read Your Vial

Why '20 units' means nothing without the vial's mg/mL. The formula, conversion tables for semaglutide and tirzepatide, the 28-day rule and the FDA's error reports.

Updated November 15, 2026

Medical reviewer

How we review

Key takeaways

  • A 'unit' on an insulin syringe is a volume (100 units = 1 mL), not a dose. The same 0.25 mg of semaglutide is 25 units from a 1 mg/mL vial, 10 units from a 2.5 mg/mL vial and 5 units from a 5 mg/mL vial. Instructions written only in units are the root of the errors the FDA has logged.
  • The FDA's reports include patients who drew 50 units instead of 5, a prescriber who wrote 25 units meaning 0.25 mg (5 units), and 20 units written instead of 2: doses five to twenty times too high, with vomiting, dehydration, fainting, pancreatitis and gallstones among the results.
  • Three numbers must appear together before you inject: the dose in mg, the vial's concentration in mg/mL, and the resulting volume in mL (and units). If any one is missing, call the pharmacy before you draw up. The formula is mL = mg ÷ mg/mL.
  • FDA says to discard a multi-dose vial 28 days after first use even if drug remains, so a vial's total mg rarely equals usable doses; at the labelled starting doses, that often means buying more than you inject. The FDA-approved labels (Wegovy, Zepbound) are the reference your prescriber works from for every dose step.

What do the 'units' on a compounded semaglutide vial mean?

Woman reading the concentration label on a small compounded medication vial next to an insulin syringe and a notepad
The short answerUnits are a measure of volume, not of medicine. The insulin syringes used for compounded GLP-1 injections are "U-100" syringes: 100 units equals 1 mL, so 10 units is 0.1 mL and 5 units is 0.05 mL. How much semaglutide or tirzepatide sits in that volume depends entirely on the vial's concentration, printed as milligrams per millilitre (mg/mL). Your prescribed dose is a weight in mg. The units are only the answer to "how far do I pull the plunger," and that answer changes every time the concentration changes.

This is the single idea that explains the dosing errors the FDA alerted prescribers, compounders and patients about (content current as of July 26, 2024). The approved products hide the arithmetic: a Wegovy pen delivers a fixed dose with no measuring, and a Zepbound vial is a single dose drawn up whole. Compounded products often come as multi-dose vials in varying concentrations, and the FDA notes that instructions may tell patients to inject a number of "units," a figure whose meaning shifts with the concentration. Our own medical reviewer flagged the same point on our weight-loss hub: compounded instructions should state the dose in mg, the concentration, and the matching syringe volume, because units alone cause confusion.

This page gives you the formula, conversion tables at example concentrations for both molecules, the 28-day vial math, how to choose a syringe, and the red flags that should stop you before you inject. It is not a dosing instruction. The dose on your prescription, written by a licensed prescriber who knows your history, is the only one that applies to you; this page is for checking that the numbers on your vial, your syringe and your prescription agree. Compounded medicines are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality.

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

What went wrong in the FDA's dosing-error reports?

The FDA's alert describes the pattern in concrete cases. Most reports involved patients drawing more than the prescribed amount from a multi-dose vial during self-injection, taking "five to 20 times more than the intended dose." The individual cases it cites:

What happenedIntendedActualMultiple
Patient told to draw 5 units (0.05 mL) on a U-100 syringe drew 50 units5 units50 units10x
Prescriber meant 0.25 mg (5 units at that concentration) but wrote 25 units; the patient had severe vomiting5 units25 units5x
Prescriber wrote 20 units instead of 2 units; three patients received the dose and had nausea and vomiting2 units20 units10x
Patient could not get clear instructions from the telemedicine prescriber, searched online, and took five times the dose1x5x5x
A patient who was also a clinician recalculated the dose in units and self-administered ten times the intended amount1x10x10x

The reported effects were nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones; some patients were hospitalised. The FDA's page on unapproved GLP-1 drugs (current as of October 1, 2026) adds that it has received "multiple reports of adverse events, some requiring hospitalization," that may relate to these errors, and that in some cases the error was the clinician miscalculating rather than the patient.

Notice what every case has in common. None involved a defective product. Each was a conversion failure: a dose in mg turned into a number of units without the concentration being carried through, or a decimal lost between a prescription and a syringe. That is why the fix is arithmetic and labelling, and why the FDA's recommendations are about syringes and instructions, not the drug.

How do you convert mg to mL and units?

Two lines, applied in order, every time:

The formula

Volume (mL) = dose (mg) ÷ concentration (mg/mL)

Units on a U-100 syringe = volume (mL) × 100

Worked example. Your prescription says 0.5 mg of semaglutide once weekly and the vial says 2.5 mg/mL. Volume = 0.5 ÷ 2.5 = 0.2 mL. Units = 0.2 × 100 = 20 units. Now the same prescription with a 5 mg/mL vial: 0.5 ÷ 5 = 0.1 mL = 10 units. Same dose, half the units, because the vial is twice as strong. A patient who moves between pharmacies, or whose pharmacy changes concentration between refills, can be given the identical mg dose and need a completely different syringe reading.

A check you can run against an FDA-approved product shows the arithmetic is not a compounded-only concern. The Zepbound label (revised August 2026) lists a multi-dose vial of 10 mg in 2.4 mL that delivers four 2.5 mg doses of 0.6 mL each. Run it through the formula: 10 ÷ 2.4 = 4.17 mg/mL; 2.5 ÷ 4.17 = 0.6 mL = 60 units. The label's own numbers reconcile, which is exactly the test to apply to a compounded vial: do the total mg, the total mL and the per-dose volume on the instructions all agree with each other?

Three habits prevent most mistakes. Write the three numbers (mg, mg/mL, mL) on the vial box in your own hand after confirming them with the pharmacist. Re-do the arithmetic whenever a new vial arrives, even from the same pharmacy. And never convert a dose into units from memory; the number you remember belongs to the last concentration, not necessarily this one.

Semaglutide conversion table: dose, concentration, volume, units

The doses in the left column are the escalation steps in the Wegovy prescribing information (revised June 2026): 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then a maintenance dose of 1.7 mg or 2.4 mg. The concentrations across the top are examples chosen to show how the volume moves; your vial may say something else, and that number, not this table, governs your draw. Units assume a U-100 syringe.

Weekly dose1 mg/mL vial2.5 mg/mL vial5 mg/mL vial
0.25 mg (weeks 1 to 4 on the label)0.25 mL = 25 units0.1 mL = 10 units0.05 mL = 5 units
0.5 mg (weeks 5 to 8)0.5 mL = 50 units0.2 mL = 20 units0.1 mL = 10 units
1 mg (weeks 9 to 12)1 mL = 100 units0.4 mL = 40 units0.2 mL = 20 units
1.7 mg (weeks 13 to 16, or maintenance)1.7 mL = 170 units (more than one syringe)0.68 mL = 68 units0.34 mL = 34 units
2.4 mg (maintenance)2.4 mL = 240 units (more than one syringe)0.96 mL = 96 units0.48 mL = 48 units

Read the table across a row and the problem the FDA describes is visible: the starting 0.25 mg dose is 5 units from one vial and 25 units from another. A "25 units" instruction written for the 1 mg/mL vial, carried over to a 5 mg/mL vial, delivers 1.25 mg, five times the intended dose, which is precisely one of the FDA's cases. Read down a column and the second point appears: the right-hand vials put maintenance doses within a single 1 mL syringe, while the 1 mg/mL vial does not, which is one reason concentrations vary between pharmacies.

The label's schedule is the reference your prescriber works from, including its instruction to consider delaying an increase by four weeks if a dose is not tolerated. Whether and when you move between rows is the prescriber's decision, not the table's; doses are increased step by step under supervision, and a missed-dose rule exists for a reason (on the injection label, two or more consecutive missed doses mean restarting escalation at a lower dose).

What To Know Before Starting GLP-1 Treatment

Before starting GLP-1 treatment, it's important to understand a few key things. These medications require a prescription from a licensed clinician and aren't suitable for everyone. Some people may experience side effects, especially during the first few weeks as the body adjusts.

GLP-1s also tend to work best when combined with basic lifestyle habits like balanced nutrition and regular physical activity.

That's why choosing a provider that offers proper medical screening and ongoing follow-up support is essential for both safety and long-term success.

Woman preparing GLP-1 weight loss injection

Tirzepatide conversion table: dose, concentration, volume, units

Tirzepatide's labelled steps are wider. The Zepbound label starts at 2.5 mg once weekly for four weeks (a starting dose only, "not approved as a maintenance dosage"), then 5 mg, with any further increase in 2.5 mg steps after at least four weeks on the current dose, to a maximum of 15 mg. Again, the concentrations are examples; the volume in your instructions must come from your own vial.

Weekly dose5 mg/mL vial10 mg/mL vial20 mg/mL vial
2.5 mg (first 4 weeks on the label)0.5 mL = 50 units0.25 mL = 25 units0.125 mL = 12.5 units
5 mg1 mL = 100 units0.5 mL = 50 units0.25 mL = 25 units
7.5 mg1.5 mL = 150 units (more than one syringe)0.75 mL = 75 units0.375 mL = 37.5 units
10 mg2 mL = 200 units (more than one syringe)1 mL = 100 units0.5 mL = 50 units
12.5 mg2.5 mL = 250 units1.25 mL = 125 units0.625 mL = 62.5 units
15 mg (label maximum)3 mL = 300 units1.5 mL = 150 units0.75 mL = 75 units

Two practical notes fall out of this table. Half-unit readings (12.5, 37.5, 62.5) only exist on syringes marked in half units; if your syringe is marked in whole or two-unit steps, a concentration that produces a half-unit volume is a reason to ask the pharmacy for a different syringe or a different concentration rather than to round. And at the top of the range, a 5 mg/mL product needs more than one full 1 mL syringe per injection, which multiplies the chances of a counting error. The Zepbound label's own guidance for its vials is to use "a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose)," and to use a new syringe and needle every time.

For the clinical side of tirzepatide dosing (why the label pauses four weeks between steps, and what the 72-week SURMOUNT results measured at each maintenance dose), see tirzepatide vs semaglutide.

How do you read a compounded vial label, line by line?

A compounded vial label is written by the pharmacy, so layouts vary, but the information you need is always the same five items. If you cannot find one of them, that is a phone call, not a guess.

Look forWhat it tells youIf it is missing
Drug name and salt formIt should say semaglutide or tirzepatide. The FDA says "semaglutide sodium" and "semaglutide acetate" are different active ingredients from the approved drug and that it is "not aware of any lawful basis for their use in compounding."Ask the pharmacy in writing which active ingredient was used.
Concentration (mg/mL)The number that converts your mg dose into a volume. Sometimes printed as total mg and total mL instead (for example 5 mg / 2 mL = 2.5 mg/mL).Do not inject. Without it, no number of units can be checked.
Total volume and total mgHow many doses the vial physically holds, before the 28-day rule (next section).Ask; it also tells you whether the vial was overfilled or underfilled relative to the price you paid.
Beyond-use dateThe pharmacy's date after which the product should not be used, separate from the 28-days-after-opening rule.Ask for it; a vial without one has no documented stability.
Dose instruction in mg, mL and unitsAll three, agreeing with each other and with the concentration. The FDA tells prescribers to be vigilant because concentrations vary, and to contact the compounder if uncertain.Call the prescriber before the first injection; ask them to confirm the mL figure, not just the units.

Keep the vial box and the pharmacy's information sheet until the vial is finished. If a refill arrives with a different concentration, or a different total volume, treat it as a new product and redo the arithmetic from the top.

Shop semaglutide plans by provider

Published semaglutide plans - cheapest first, conditions under each price.

Which syringe should you use for compounded GLP-1 injections?

Insulin syringes come in three common barrel sizes, and the FDA's alert asks prescribers and compounders to "provide a syringe size appropriate for the intended dose" and to counsel patients on measuring with it. The reason is precision: the smaller the barrel, the finer the markings.

U-100 syringeHoldsTypical markingsSuits volumes of
0.3 mL (30-unit)30 unitsFinest; half-unit versions existUp to 0.3 mL: most semaglutide doses at 2.5 mg/mL and above
0.5 mL (50-unit)50 unitsFine0.3 to 0.5 mL
1 mL (100-unit)100 unitsCoarsest0.5 to 1 mL: higher tirzepatide doses at 10 mg/mL

Two errors in the FDA's reports were a plain tenfold misreading (5 units drawn as 50). On a 1 mL syringe, 5 units is a sliver near the needle hub and the 50-unit line sits mid-barrel; on a 0.3 mL syringe, 5 units is a clearly visible fifth of the barrel and 50 units does not exist. Matching the syringe to the dose is not a convenience; it removes the most common wrong answer from the syringe entirely. If the pharmacy shipped syringes that cannot read your volume accurately, ask for the right size before you start.

Always use a new sterile needle and syringe for each dose, as both FDA pages state. Insulin syringes are single-use.

How many doses does a multi-dose vial really give you?

Fewer than the label's total mg suggests, because of the 28-day rule. The FDA's position, stated on its unapproved GLP-1 page, is that multi-dose sterile vials should generally be used within 28 days after first use, because the risk of contamination rises after that; discard the vial 28 days after the first puncture even if medication remains, and "do not continue using medication from the vial after 28 days" even if the compounder says it can be used longer.

At once-weekly dosing, 28 days is four injections. So the usable doses in a vial are the lesser of what it physically holds and four. The table shows what that means at the labelled semaglutide starting steps for a 1 mL vial at 2.5 mg/mL (2.5 mg total):

Weekly doseDoses the vial holdsDoses usable in 28 daysmg injectedmg discarded
0.25 mg1041 mg1.5 mg (60%)
0.5 mg542 mg0.5 mg (20%)
1 mg2 (plus a half)22 mg0.5 mg, and a third week needs a new vial

Three consequences. First, "a vial of 2.5 mg" is not "ten weeks of starting doses." Second, a plan priced per vial can cost very differently per usable dose depending on your step, which is worth knowing before you prepay; our guide to the true cost of GLP-1 treatment works through the yearly totals. Third, a vial sized so that the 28-day limit falls exactly on your fourth dose is the efficient design, and it is a fair question to ask a provider how its vial sizes line up with the labelled steps.

What dose schedule do the FDA-approved labels use?

Compounded products have no label of their own, so the approved prescribing information is the reference point for every dose step, and the document your prescriber is working from. Both labels increase slowly for a reason: gastrointestinal side effects cluster after each increase, and the labels allow a pause when a step is not tolerated.

Semaglutide injection (Wegovy label, revised 6/2026)Tirzepatide injection (Zepbound label, revised 8/2026)
Starting dose0.25 mg once weekly for 4 weeks2.5 mg once weekly for 4 weeks (starting dose only)
Escalation0.5 mg (weeks 5 to 8), 1 mg (9 to 12), 1.7 mg (13 to 16)5 mg after 4 weeks, then 2.5 mg steps after at least 4 weeks on each
Maintenance for weight reduction1.7 mg or 2.4 mg once weekly; the June 2026 label adds a 7.2 mg option (Wegovy HD) only after 2.4 mg has been tolerated for at least 4 weeks and more weight loss is clinically indicated5, 10 or 15 mg once weekly; 15 mg is the maximum
If a step is not toleratedConsider delaying escalation by 4 weeksStay at least 4 weeks on each dose before increasing
Missed doseTake it if the next dose is more than 2 days away; otherwise skip. Two or more missed in a row: restart escalation at a lower doseTake within 4 days (96 hours); after that, skip and resume on schedule
Approved presentationsSingle-dose pens and syringes from 0.25 mg/0.5 mL to 2.4 mg/0.75 mL; a multi-dose pen of 9.6 mg/3 mL; tablets (1.5, 4, 9 and 25 mg, escalated every 30 days)Single-dose pens and vials 2.5 to 15 mg in 0.5 mL; a multi-dose vial of four doses (for example 10 mg/2.4 mL)

Two things in that table matter for a compounded patient. The approved products never ask the patient to convert anything: a Wegovy 0.25 mg pen is 0.25 mg, and a Zepbound 2.5 mg vial is drawn up whole. The only approved product that involves a per-dose volume, the Zepbound multi-dose vial, comes with the volume (0.6 mL) printed on the label. That is the standard your compounded instructions should meet. And every schedule above is a prescriber's framework; our dose schedule tool maps the labelled steps onto a calendar, but when you move between steps is a decision made with the person who prescribed the drug.

Red flags that should stop you before you inject

  • Instructions only in units. The FDA's alert identifies units-only instructions as a source of the errors. Ask for the mg and the mL.
  • No concentration anywhere on the vial, the box or the information sheet.
  • Numbers that do not reconcile. If dose ÷ concentration does not equal the stated volume, one of the three is wrong. Do not pick one; call.
  • A refill at a different concentration with the same "units" instruction. This is the five-times case in the FDA's reports.
  • Being told the vial is fine past 28 days. The FDA's advice is to discard at 28 days regardless of what the compounder says.
  • "Semaglutide sodium" or "semaglutide acetate" on the label, which the FDA says are not the approved active ingredient.
  • Dose changes without the prescriber. A member of a support group being "kept on" a higher dose is one person's history, not your starting point; increases happen under prescriber supervision, in the labelled steps.
  • Any product bought without a prescription from a state-licensed pharmacy. The FDA's guidance is to fill a prescription from your own doctor at a licensed pharmacy; outside that route there is no one accountable for the concentration at all.

What should you do if you think you injected too much?

Call your prescriber or the pharmacy immediately, and in the United States you can also call Poison Help at 1-800-222-1222 (poisonhelp.org), which is free and staffed around the clock. Tell them the drug, the concentration on the vial, the volume you drew and the volume you were meant to draw. Keep the vial and syringe.

The effects the FDA has recorded after overdoses are severe nausea and vomiting, abdominal pain, dehydration, fainting, headache, acute pancreatitis and gallstones. Persistent severe abdominal pain, an inability to keep fluids down, or fainting are reasons for urgent in-person assessment, not for waiting to see. If you take insulin or a sulfonylurea as well, low blood sugar is an added risk and your blood sugar should be checked. Do not take the next weekly dose until the prescriber has told you how to restart; both labels have rules for gaps in dosing, and after a large overdose the restart is a clinical decision.

Where do the providers we rank fit in?

Every weight-loss provider we rank prescribes through a licensed clinician and dispenses through a state-licensed pharmacy, and we read each one's public pages and verify its published price before it appears here; our ranking method explains what we check. What we do not do is independently test vial concentrations or review the written instructions each pharmacy ships, so this page is the checklist to apply to any provider, including the two shown below. The questions to ask before your first injection: the dose in mg, the concentration in mg/mL, the volume in mL and units, the syringe size they ship, and how many usable doses the vial gives within 28 days.

If the answers come back quickly and consistently, that is a good sign about the pharmacy behind the provider. If they come back only as "inject 20 units," you now know why that is not an answer, and what to ask for instead. For how the prescription process works end to end, see how to start GLP-1 treatment online; for the safety screening a prescriber should run before any of this arithmetic matters, the safety section of our weight-loss hub lists the points from the labels.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)